Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, parallel-group multi-center study of Phase 3 study to
assess the efficacy and safety of KN035 compared to standard of care (SOC) Gemcitabine-based
chemotherapies in the treatment of participants with previously untreated locally advanced or
metastatic biliary tract cancer.
The primary hypothesis of this study is that participants will have a longer overall Survival
(OS) when treated with combined therapy than SOC.